Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Schering-Plough announced today that the European Commission has granted approval of Temodal (temozolomide) Capsules for first-line use for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.
Yale School of Medicine scientists have identified a virus that targets and kills glioblastoma, a deadly type of human brain tumor resistant to current medical or surgical treatment, according to a study published as the cover article in the Journal of Virology.
Researchers at Wake Forest University Baptist Medical Center have found promising new molecular targets and treatment approaches for some of the most malignant brain tumors.
The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.
The nucleus of an atom contains protons and neutrons. However, some atoms of the same chemical element can have varying numbers of neutrons, giving so-called isotopes of that element.
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.
A large international study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with the National Cancer Institute of Canada (NCIC) Clinical Trials Group demonstrated that the addition of a novel chemotherapy agent, Temozolomide (brand name: Temodal®) to radiation therapy increases survival in patients suffering from glioblastoma, a very aggressive form of a brain tumour.
An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.
When he's not in the operating room performing surgery, Donald M. O'Rourke, M.D., Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine is fighting brain tumors from the research laboratory bench.
A Finnish research group has been the first in the world to publish an article in which BNCT treatment has had an excellent response in a patient with head and neck cancer for whom there was no other treatment available.
Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have found that the combination of immunotherapy and chemotherapy significantly slowed tumor progression and extended survival of patients with glioblastoma multiforme (GBM).
Cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to brain tumors by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).
Virginia Commonwealth University Massey Cancer Center researchers have found that combining ionizing radiation with a secreted protein that selectively inhibits tumor cell growth and survival can target cancer cells and leave healthy cells alone, perhaps presenting a new approach for treating the deadliest type of brain tumor.
The use of a "smart" drug that targets cancer cells in the brain following removal of a tumor may provide treatment that can extend the survival of people with the most common form of primary malignant brain tumor, glioblastoma multiforme (GBM).
When molecules in cells are stimulated by light, they respond by becoming excited and re-emitting light of varying colors (fluorescence) that can be captured and measured by highly sensitive optical equipment.
Researchers seeking to direct cancer-killing immune cells against the deadliest brain tumors have three new targets that show promise in laboratory studies and in a Phase I patient trial, according to two articles in the July 15 issue of the journal Cancer Research.
The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.